

Reply

Reply: “Comment on Search and Selection of Probiotics that Improve Mucositis Symptoms in Oncologic Patients. A Systematic Review. *Nutrients* 2019, 11, 2322”

José Antonio Picó-Monllor ^{1,2,*}  and José Manuel Mingot-Ascencao ²

¹ Department of Pharmacology, Pediatrics and Organic Chemistry, Faculty of Pharmacy, Universidad Miguel Hernández, 03200 Elche, Spain

² Korott, s.l., 03801 Alcoy, Spain; jmtingot@korott.com

* Correspondence: japico@korott.com or japico@umh.es; Tel.: +34-966526550

Received: 2 January 2020; Accepted: 4 January 2020; Published: 3 February 2020



In the article, “Search and Selection of Probiotics That Improve Mucositis Symptoms in Oncologic Patients. A Systematic Review” [1] which appears in Volume 11, Issue 10 of *Nutrients*, there is a correction on the official term of the drug name used in the article.

As De Simone [2] points out, The drug term VSL#3[®] is replaced with the generic name of the formulation, “De Simone formulation”, following a legal dispute between the distributors of the product VSL#3[®] and the formula inventor.

This change does not affect the study of the paper.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Picó-Monllor, J.A.; Mingot-Ascencao, J.M. Search and selection of probiotics that improve mucositis symptoms in oncologic patients: A systematic review. *Nutrients* **2019**, *11*, 2322. [[CrossRef](#)] [[PubMed](#)]
2. De Simone, C. Comment on: “Search and selection of probiotics that improve mucositis symptoms in oncologic patients: A systematic review. *Nutrients* 2019, 11, 2322”. *Nutrients* **2020**, *12*, 399.



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).